Skip to main content
Top
Published in: BMC Cancer 1/2009

Open Access 01-12-2009 | Research article

Certified causes of death in patients with mesothelioma in South East England

Authors: Catherine Okello, Tom Treasure, Andrew G Nicholson, Julian Peto, Henrik Møller

Published in: BMC Cancer | Issue 1/2009

Login to get access

Abstract

Background

Mesothelioma is a highly fatal cancer that is caused by exposure to asbestos fibres. In many populations, the occurrence of mesothelioma is monitored with the use of mortality data from death certification. We examine certified causes of death of patients who have been diagnosed with mesothelioma, and assess the validity of death certification data as a proxy for mesothelioma incidence.

Methods

We extracted mesothelioma registrations in the South East of England area between 2000 and 2004 from the Thames Cancer Registry database. We retained for analysis 2200 patients who had died at the time of analysis, after having excluded seven dead cases where the causes of death were not known to the cancer registry. The 2200 deaths were classified hierarchically to identify (1) mesothelioma deaths, (2) deaths certified as lung cancer deaths or (3) deaths from unspecified cancer, and (4) deaths from other causes.

Results

87% of the patients had mesothelioma mentioned on the death certificate. 6% had no mention of mesothelioma but included lung cancer as a cause of death. Another 6% had no mention of mesothelioma or lung cancer, but included an unspecified cancer as a cause of death. Lastly, 2% had other causes of death specified on the death certificate.

Conclusion

This analysis suggests that official mortality data may underestimate the true occurrence of mesothelioma by around 10%.
Literature
1.
go back to reference Chapman A, Mulrennan S, Ladd B, Muers MF: Population-based epidemiology and prognosis of mesothelioma in Leeds, United Kingdom. Thorax. 2008, 63: 435-9. 10.1136/thx.2007.081430.CrossRefPubMed Chapman A, Mulrennan S, Ladd B, Muers MF: Population-based epidemiology and prognosis of mesothelioma in Leeds, United Kingdom. Thorax. 2008, 63: 435-9. 10.1136/thx.2007.081430.CrossRefPubMed
2.
go back to reference Mak V, Davies E, Putcha V, Choodari-Oskooei B, Møller H: The epidemiology and treatment of mesothelioma in South East England 1985–2002. Thorax. 2008, 63: 160-6. 10.1136/thx.2006.066886.CrossRefPubMed Mak V, Davies E, Putcha V, Choodari-Oskooei B, Møller H: The epidemiology and treatment of mesothelioma in South East England 1985–2002. Thorax. 2008, 63: 160-6. 10.1136/thx.2006.066886.CrossRefPubMed
3.
go back to reference Hodgson JT, McElvenny DM, Darnton AJ, Price MJ, Peto J: The expected burden of mesothelioma mortality in Great Britain from 2002 to 2050. Br J Cancer. 2005, 92: 587-93.PubMedPubMedCentral Hodgson JT, McElvenny DM, Darnton AJ, Price MJ, Peto J: The expected burden of mesothelioma mortality in Great Britain from 2002 to 2050. Br J Cancer. 2005, 92: 587-93.PubMedPubMedCentral
4.
go back to reference Camidge DR, Stockton DL, Bain M: Factors affecting the mesothelioma detection rate within national and international epidemiological studies: insights from Scottish linked cancer registry-mortality data. Br J Cancer. 2006, 95: 649-52. 10.1038/sj.bjc.6603293.CrossRefPubMedPubMedCentral Camidge DR, Stockton DL, Bain M: Factors affecting the mesothelioma detection rate within national and international epidemiological studies: insights from Scottish linked cancer registry-mortality data. Br J Cancer. 2006, 95: 649-52. 10.1038/sj.bjc.6603293.CrossRefPubMedPubMedCentral
5.
go back to reference Goldacre MJ: Cause-specific mortality: understanding uncertain tips of the disease iceberg. J Epidemiol Community Health. 1993, 47: 491-6. 10.1136/jech.47.6.491.CrossRefPubMedPubMedCentral Goldacre MJ: Cause-specific mortality: understanding uncertain tips of the disease iceberg. J Epidemiol Community Health. 1993, 47: 491-6. 10.1136/jech.47.6.491.CrossRefPubMedPubMedCentral
6.
go back to reference Johansson LA, Westerling R: Comparing Swedish hospital discharge records with death certificates: implications for mortality statistics. Int J Epidemiol. 2000, 29 (3): 495-502. 10.1093/ije/29.3.495.CrossRefPubMed Johansson LA, Westerling R: Comparing Swedish hospital discharge records with death certificates: implications for mortality statistics. Int J Epidemiol. 2000, 29 (3): 495-502. 10.1093/ije/29.3.495.CrossRefPubMed
7.
go back to reference Muers MF, Stephens RJ, Fisher P, Darlison L, Higgs CMB, Lowry E, Nicholson AG, O'Brien Peake M, Rudd R, Snee M, Steele J, Girling DJ, Nankivell M, Pugh C, Parmar MKB, on behalf of the MS01 Trial Management Group: Active symptom control with or without chemotherapy in the treatment of patients with malignant pleural mesothelioma: Results of the Medical Research Council/British Thoracic Society MS01 multi-centre randomised trial (ISRCTN54469112). Lancet. 2008, 17: 1685-94. 10.1016/S0140-6736(08)60727-8.CrossRef Muers MF, Stephens RJ, Fisher P, Darlison L, Higgs CMB, Lowry E, Nicholson AG, O'Brien Peake M, Rudd R, Snee M, Steele J, Girling DJ, Nankivell M, Pugh C, Parmar MKB, on behalf of the MS01 Trial Management Group: Active symptom control with or without chemotherapy in the treatment of patients with malignant pleural mesothelioma: Results of the Medical Research Council/British Thoracic Society MS01 multi-centre randomised trial (ISRCTN54469112). Lancet. 2008, 17: 1685-94. 10.1016/S0140-6736(08)60727-8.CrossRef
8.
go back to reference Cury PM, Butcher DN, Fisher C, Corrin B, Nicholson AG: The value of the mesothelium-associated antibodies, thrombomodulin, cytokeratin 5/6, calretinin and CD44H in distinguishing epithelioid pleural mesothelioma from adenocarcinoma metastatic to the pleura. Modern Pathology. 2000, 13: 107-12. 10.1038/modpathol.3880018.CrossRefPubMed Cury PM, Butcher DN, Fisher C, Corrin B, Nicholson AG: The value of the mesothelium-associated antibodies, thrombomodulin, cytokeratin 5/6, calretinin and CD44H in distinguishing epithelioid pleural mesothelioma from adenocarcinoma metastatic to the pleura. Modern Pathology. 2000, 13: 107-12. 10.1038/modpathol.3880018.CrossRefPubMed
Metadata
Title
Certified causes of death in patients with mesothelioma in South East England
Authors
Catherine Okello
Tom Treasure
Andrew G Nicholson
Julian Peto
Henrik Møller
Publication date
01-12-2009
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2009
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/1471-2407-9-28

Other articles of this Issue 1/2009

BMC Cancer 1/2009 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine